HF-GRO awards set to fund pre-clinical research in aging biology and geroscience.
Hevolution Foundation has added to its funding line-up with a new grants program. HF-GRO (or Hevolution Foundation – Geroscience Research Opportunities to give it its full moniker) will provide funding for pre-clinical research in aging biology and geroscience in the United States, Canada, and Europe.
Longevity.Technology: Headquartered in Riyadh, Hevolution is a non-profit organization that is on a mission to extend healthy human lifespan by understanding the processes of aging. Backed by an annual budget of up to $1 billion, the Foundation provides grants and early-stage investments to incentivize research and entrepreneurship in healthspan science, and this new grants program boasts a budget of up to $25 million for the remainder of 2023, and up to $115 million over the next five years.
“We see HF-GRO as a major step on the path to funding a significant amount of promising aging biology and geroscience research on an international scale,” said Felipe Sierra PhD, Hevolution Foundation’s Chief Scientific Officer. “We anticipate releasing calls covering other geographic areas in the coming months.”
Funded projects are expected to last four to five years, with direct costs of each project anticipated to be in the range of $300,000 to $500,000 annually. The HF-GRO Awards are for basic and translational research only, and will not be used to fund clinical trials.
The American Federation for Aging Research (AFAR) is providing programmatic support for the HF-GRO program for Hevolution Foundation. Information and related materials about this funding opportunity may be found here.
